Jim Cramer: This Energy Stock Is A 'Winner,' But Navitas Semiconductor Is 'Losing A Lot Of Money'
Jim Cramer: This Energy Stock Is A 'Winner,' But Navitas Semiconductor Is 'Losing A Lot Of Money'
On Nov. 15, the FDA accepted for review the resubmission of the supplemental biologics license application (sBLA) for Regeneron Pharmaceuticals and On CNBC's "Mad Money Lightning Round," Jim Cramer said Navitas Semiconductor Corporation (NASDAQ:NVTS) is "losing a lot of money."
在CNBC的《瘋狂金錢閃電環節》中，吉姆·克萊默表示Navitas半導體公司（納斯達克：NVTS）正在「虧損很多」。
On Tuesday, Navitas Semiconductor announced that Dr. Ranbir Singh, formerly executive vice president at Navitas and the founder and CEO of GeneSiC Semiconductor, has been appointed to the company's board of directors.
週二，Navitas半導體宣佈，前執行副總裁蘭比爾·辛格博士被任命爲公司董事會成員。
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a "quandary. I've got to tell you, I expected sales to be better," Cramer said. "I do prefer Eli Lilly (NYSE:LLY)."
再生元製藥公司（納斯達克：REGN）是一種「困境。我得告訴你，我原本預期銷售會更好，」克萊默說道。「我更喜歡艾爾利製藥（紐交所：LLY）。」
On Nov. 15, the FDA accepted for review the resubmission of the supplemental biologics license application (sBLA) for Regeneron Pharmaceuticals and Sanofi SA's (NASDAQ:SNY) Dupixent (dupilumab) for patients ages 12 years and older with chronic spontaneous urticaria (CSU) whose disease is not adequately controlled with H1 antihistamine treatment. Wolfe Research analyst Alexandria Hammond initiated coverage on Regeneron Pharmaceuticals with an Outperform rating and announced a price target of $1150.
11月15日，FDA接受了再生元製藥和賽諾菲安萬特（納斯達克：SNY）針對12歲及以上慢性自發性蕁麻疹（CSU）患者的Dupixent（dupilumab）的補充生物製品許可證申請（sBLA）重新提交的審核。沃爾夫研究分析師亞歷山德拉·哈蒙德對再生元製藥啓動了優於大盤的評級，並宣佈目標價格爲1150美元。
Cramer said LandBridge Company LLC (NYSE:LB) is a "winner." He recommended holding on to the stock.
克萊默表示LandBridge公司（紐交所：LB）是一個「贏家。」他建議持有該股票。
On Nov. 7, LandBridge reported quarterly sales of $28.487 million, which missed the analyst consensus estimate of $33.323 million. On Dec. 4, Piper Sandler analyst Mark Lear maintained LandBridge with a Neutral rating and raised the price target from $39 to $79.
在11月7日，LandBridge報告季度銷售額爲2848.7萬，低於分析師的共識預期3332.3萬。12月4日，派傑投資分析師馬克·李爾維持LandBridge的中立評級，並將目標價格從39美元提高到79美元。
Price Action:
價格行動：
- Navitas Semiconductor shares gained 4% to settle at $3.14 on Tuesday.
- Regeneron Pharmaceuticals shares fell 1.7% to close at $749.57.
- LandBridge shares gained 2.8% to close at $74.84 on Tuesday.
- Navitas半導體的股票在週二上漲4%，收於3.14美元。
- 再生元製藥公司的股票下跌1.7%，收盤價爲749.57美元。
- 陸橋公司的股票在週二上漲2.8%，收盤價爲74.84美元。
- Jim Cramer Prefers FedEx Over This Delivery Giant That 'Screwed Up A Lot Of Holiday Seasons'
- 吉姆·克萊默更喜歡聯邦快遞，而不是這家曾經「搞砸了很多個假期季節」的快遞巨頭。
Photo: Shutterstock
Photo: shutterstock
譯文內容由第三人軟體翻譯。
